Methods of Glycemic Control and Neonatal Outcomes after Antenatal Corticosteroid Administration among Women with Pregestational DiabetesFunding None.
Objective The objective of this study was to evaluate the association between the method of maternal glycemic control after antenatal corticosteroid, administration and maternal hyperglycemia and neonatal morbidity among women with diabetes.
Study Design This was a retrospective cohort study of women with pregestational diabetes who received antenatal corticosteroids and delivered in <34 weeks. The primary maternal outcome was adequate glycemic control, defined as <50% of glucose values above goal (fasting <100 mg/dL, 2-hour postprandial <120 mg/dL, or <115 mg/dL on insulin infusion). The primary neonatal outcome was composite morbidity (continuous positive airway pressure, mechanical ventilation, intraventricular hemorrhage, or death). Demographic characteristics and outcomes were compared by the method of glycemic control and neonatal morbidity using chi-square test, Fisher's exact test, Mann–Whitney U-test, and Student's t-test, as appropriate.
Results Of 52 eligible women, only 1 (1.9%) had adequate maternal glycemic control. There was no significant association between the method of glycemic control and maternal hyperglycemia or neonatal morbidity. There was no association between maternal glucose and neonatal morbidity; however, neonates with composite morbidity were more likely to be born to women who received less insulin.
Conclusion Maternal glycemic control among women with diabetes was poor after the antenatal corticosteroid administration, regardless of glycemic control method. Neither the method of maternal glycemic control nor the degree of control was associated with neonatal morbidity.
Received: 25 March 2019
Accepted: 07 June 2019
31 July 2019 (online)
© 2020. Thieme. All rights reserved.
Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.
- 1 Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; 3: CD004454
- 2 ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol 2005; 105 (03) 675-685
- 3 American Diabetes Association. 13. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41 (Suppl. 01) S137-S143
- 4 Refuerzo JS, Garg A, Rech B, Ramin SM, Vidaeff A, Blackwell SC. Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: a pilot study. Am J Perinatol 2012; 29 (05) 335-338
- 5 Committee on Obstetric Practice; El-Sayed YY, Borders AEB, Gyamfi-Bannerman C. Committee opinion no. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2017; 130 (02) e102-e109
- 6 Committee on Obstetric Practice. ACOG Committee Opinion: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2002; 99 (5, Pt 1): 871-873
- 7 Amiya RM, Mlunde LB, Ota E, Swa T, Oladapo OT, Mori R. Antenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis. PLoS One 2016; 11 (02) e0147604
- 8 Piper JM, Xenakis EMJ, Langer O. Delayed appearance of pulmonary maturation markers is associated with poor glucose control in diabetic pregnancies. J Matern Fetal Med 1998; 7 (03) 148-153
- 9 Kaushal K, Gibson JM, Railton A, Hounsome B, New JP, Young RJ. A protocol for improved glycaemic control following corticosteroid therapy in diabetic pregnancies. Diabet Med 2003; 20 (01) 73-75
- 10 Kalra S, Kalra B, Gupta Y. Glycemic management after antenatal corticosteroid therapy. N Am J Med Sci 2014; 6 (02) 71-76
- 11 Ramírez-Torres MA, Pérez-Monter SE, Espino y Sosa S, Ibargüengoitia-Ochoa F. Effect of betamethasone in blood glucose levels in pregnant diabetic women at risk of preterm birth. Ginecol Obstet Mex 2011; 79 (09) 565-571
- 12 Hare JW, White P. Gestational diabetes and the White Classification. Diabetes Care 1980; 3 (02) 394
- 13 Mathiesen ER, Christensen AB, Hellmuth E, Hornnes P, Stage E, Damm P. Insulin dose during glucocorticoid treatment for fetal lung maturation in diabetic pregnancy: test of an algorithm [correction of analgoritm]. Acta Obstet Gynecol Scand 2002; 81 (09) 835-839
- 14 Warburton D. Chronic hyperglycemia with secondary hyperinsulinemia inhibits the maturational response of fetal lamb lungs to cortisol. J Clin Invest 1983; 72 (02) 433-440
- 15 Metzger BE, Buchanan TA, Coustan DR. et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007; 30 (Suppl. 02) S251-S260
- 16 Miracle X, Di Renzo GC, Stark A, Fanaroff A, Carbonell-Estrany X, Saling E. Coordinators of World Association of Perinatal Medicine Prematurity Working Group. Guideline for the use of antenatal corticosteroids for fetal maturation. J Perinat Med 2008; 36 (03) 191-196
- 17 Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 2008; 31 (05) 899-904
- 18 Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag 2017; 20 (01) 6-12